| scholarly article | Q13442814 |
| P2093 | author name string | G Herrero-Beaumont | |
| J Egido | |||
| O Sánchez-Pernaute | |||
| R Largo | |||
| E Montell | |||
| L Ortega | |||
| R Granados | |||
| J Vergés | |||
| M E Marcos | |||
| P2860 | cites work | A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. | Q55033577 |
| Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction | Q57260454 | ||
| The antigen induced arthritis model: the relevance of the method of induction to its use as a model of human disease | Q69551617 | ||
| Cardiovascular mortality in patients with rheumatoid arthritis | Q69586053 | ||
| Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig | Q70742151 | ||
| New Rabbit Atherosclerosis Model for the Investigation of Transluminal Angioplasty | Q72769698 | ||
| Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis | Q73267274 | ||
| Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis | Q73490957 | ||
| Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells | Q74404685 | ||
| A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit | Q74445926 | ||
| Anti-inflammatory activity of chondroitin sulfate | Q77320493 | ||
| Fibrin generated in the synovial fluid activates intimal cells from their apical surface: a sequential morphological study in antigen-induced arthritis | Q78739155 | ||
| Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1 | Q79348468 | ||
| G-CSF prevents the progression of atherosclerosis and neointimal formation in rabbits | Q83114414 | ||
| Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis | Q24813839 | ||
| Novel clinical markers of vascular wall inflammation | Q28190821 | ||
| Proteoglycans in atherosclerosis and restenosis: key roles for versican | Q28261672 | ||
| Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits | Q28277242 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| NF-kappaB: a key role in inflammatory diseases | Q29617726 | ||
| Chondroitin sulfate A released from platelets blocks RANTES presentation on cell surfaces and RANTES-dependent firm adhesion of leukocytes | Q33341771 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system | Q34335964 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. | Q34570881 | ||
| Inflammation-mediated rheumatic diseases and atherosclerosis | Q35549285 | ||
| Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac | Q35637500 | ||
| The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment | Q35793760 | ||
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | Q36591918 | ||
| Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression | Q36713856 | ||
| Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. | Q40144254 | ||
| Overexpression of COX-2, Prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. | Q40364228 | ||
| Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins | Q41048276 | ||
| Experimental models of accelerated atherosclerosis syndromes | Q41204125 | ||
| Death Rate and Causes of Death in Patients with Rheumatoid Arthritis | Q42139986 | ||
| Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. | Q43833268 | ||
| Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-1alpha treated articular chondrocytes. | Q44068270 | ||
| Binding of [99mTc]chondroitin sulfate to scavenger receptors on human chondrocytes as compared to binding of oxidized [125I]LDL on human macrophages | Q44263350 | ||
| Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes | Q44394411 | ||
| Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model | Q45197823 | ||
| Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants | Q46480686 | ||
| Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month | Q46601731 | ||
| Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. | Q46921408 | ||
| Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes | Q47347418 | ||
| Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. | Q50478261 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 843-851 | |
| P577 | publication date | 2008-04-21 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis | |
| P478 | volume | 154 |
| Q37951364 | Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule |
| Q28534496 | Cholesterol diet withdrawal leads to an initial plaque instability and subsequent regression of accelerated iliac artery atherosclerosis in rabbits |
| Q40790185 | Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation |
| Q46027542 | Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. |
| Q35147261 | Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids |
| Q38724570 | Fluid shear stress induces upregulation of COX-2 and PGI2 release in endothelial cells via a pathway involving PECAM-1, PI3K, FAK, and p38. |
| Q37690217 | Hypercholesterolemia boosts joint destruction in chronic arthritis. An experimental model aggravated by foam macrophage infiltration |
| Q37310621 | Immunomodulatory and anti-inflammatory effects of chondroitin sulphate |
| Q88791008 | Osteoarthritis: Chondroitin sulfate - CONCEPT clear, uncertainties unchanged |
| Q91955976 | Reduction of osteoarthritis severity in the temporomandibular joint of rabbits treated with chondroitin sulfate and glucosamine |
| Q35001509 | Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort |
| Q37346515 | The 'sweet' and 'bitter' involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance |
| Q34840301 | Total glucosides of paeony prevents juxta-articular bone loss in experimental arthritis |
| Q33849348 | Total mortality risk in relation to use of less-common dietary supplements |
| Q36570336 | Use of glucosamine and chondroitin in relation to mortality |
Search more.